Literature DB >> 26825855

Assessing sample representativeness in randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network.

Ryoko Susukida1, Rosa M Crum1,2,3, Elizabeth A Stuart1, Cyrus Ebnesajjad1, Ramin Mojtabai1,3.   

Abstract

AIMS: To compare the characteristics of individuals participating in randomized controlled trials (RCTs) of treatments of substance use disorder (SUD) with individuals receiving treatment in usual care settings, and to provide a summary quantitative measure of differences between characteristics of these two groups of individuals using propensity score methods. Design Analyses using data from RCT samples from the National Institute of Drug Abuse Clinical Trials Network (CTN) and target populations of patients drawn from the Treatment Episodes Data Set-Admissions (TEDS-A). Settings Multiple clinical trial sites and nation-wide usual SUD treatment settings in the United States. PARTICIPANTS: A total of 3592 individuals from 10 CTN samples and 1 602 226 individuals selected from TEDS-A between 2001 and 2009. Measurements The propensity scores for enrolling in the RCTs were computed based on the following nine observable characteristics: sex, race/ethnicity, age, education, employment status, marital status, admission to treatment through criminal justice, intravenous drug use and the number of prior treatments. Findings The proportion of those with ≥ 12 years of education and the proportion of those who had full-time jobs were significantly higher among RCT samples than among target populations (in seven and nine trials, respectively, at P < 0.001). The pooled difference in the mean propensity scores between the RCTs and the target population was 1.54 standard deviations and was statistically significant at P < 0.001.
CONCLUSIONS: In the United States, individuals recruited into randomized controlled trials of substance use disorder treatments appear to be very different from individuals receiving treatment in usual care settings. Notably, RCT participants tend to have more years of education and a greater likelihood of full-time work compared with people receiving care in usual care settings.
© 2016 Society for the Study of Addiction.

Entities:  

Keywords:  Clinical trials; sample representativeness; substance use disorders

Mesh:

Year:  2016        PMID: 26825855      PMCID: PMC4899104          DOI: 10.1111/add.13327

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  37 in total

1.  Improving mental health treatments through comparative effectiveness research.

Authors:  Philip S Wang; Christine M Ulbricht; Michael Schoenbaum
Journal:  Health Aff (Millwood)       Date:  2009 May-Jun       Impact factor: 6.301

2.  The use of propensity scores to assess the generalizability of results from randomized trials.

Authors:  Elizabeth A Stuart; Stephen R Cole; Catherine P Bradshaw; Philip J Leaf
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2001-04-01       Impact factor: 2.483

3.  Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multisite effectiveness study.

Authors:  Kathleen M Carroll; Samuel A Ball; Charla Nich; Steve Martino; Tami L Frankforter; Christiane Farentinos; Lynn E Kunkel; Susan K Mikulich-Gilbertson; Jon Morgenstern; Jeanne L Obert; Doug Polcin; Ned Snead; George E Woody
Journal:  Drug Alcohol Depend       Date:  2005-09-28       Impact factor: 4.492

4.  Risk factors for 12-month comorbidity of mood, anxiety, and substance use disorders: findings from the Netherlands Mental Health Survey and Incidence Study.

Authors:  Ron de Graaf; Rob V Bijl; Filip Smit; Wilma A M Vollebergh; J Spijker
Journal:  Am J Psychiatry       Date:  2002-04       Impact factor: 18.112

5.  Determining predictors of attrition in an outpatient substance abuse program.

Authors:  Shelly L Sayre; Joy M Schmitz; Angela L Stotts; Patricia M Averill; Howard M Rhoades; John J Grabowski
Journal:  Am J Drug Alcohol Abuse       Date:  2002       Impact factor: 3.829

6.  Buprenorphine tapering schedule and illicit opioid use.

Authors:  Walter Ling; Maureen Hillhouse; Catherine Domier; Geetha Doraimani; Jeremy Hunter; Christie Thomas; Jessica Jenkins; Albert Hasson; Jeffrey Annon; Andrew Saxon; Jeffrey Selzer; Joshua Boverman; Richard Bilangi
Journal:  Addiction       Date:  2009-02       Impact factor: 6.526

7.  Area-level socioeconomic status in relation to outcomes in gamma-hydroxybutyrate intoxication.

Authors:  Ilene B Anderson; Susan Y Kim-Katz; Jo Ellen Dyer; Gillian E Earnest; John P Lamb; Paul D Blanc
Journal:  Clin Toxicol (Phila)       Date:  2009-01       Impact factor: 4.467

8.  Predictors of employment of men with HIV/AIDS: a longitudinal study.

Authors:  Judith G Rabkin; Martin McElhiney; Stephen J Ferrando; Wilfred Van Gorp; Shu Hsing Lin
Journal:  Psychosom Med       Date:  2004 Jan-Feb       Impact factor: 4.312

9.  Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Carlos Blanco; Mark Olfson; Renee D Goodwin; Elizabeth Ogburn; Michael R Liebowitz; Edward V Nunes; Deborah S Hasin
Journal:  J Clin Psychiatry       Date:  2008-08       Impact factor: 4.384

10.  A balanced iterative random forest for gene selection from microarray data.

Authors:  Ali Anaissi; Paul J Kennedy; Madhu Goyal; Daniel R Catchpoole
Journal:  BMC Bioinformatics       Date:  2013-08-27       Impact factor: 3.169

View more
  18 in total

1.  Generalizability of findings from randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network.

Authors:  Ryoko Susukida; Rosa M Crum; Cyrus Ebnesajjad; Elizabeth A Stuart; Ramin Mojtabai
Journal:  Addiction       Date:  2017-03-16       Impact factor: 6.526

2.  Generalizing Treatment Effect Estimates From Sample to Population: A Case Study in the Difficulties of Finding Sufficient Data.

Authors:  Elizabeth A Stuart; Anna Rhodes
Journal:  Eval Rev       Date:  2016-08-04

3.  Smoking-related outcomes and associations with tobacco-free policy in addiction treatment, 2015-2016.

Authors:  Joseph Guydish; Deborah Yip; Thao Le; Noah R Gubner; Kevin Delucchi; Paul Roman
Journal:  Drug Alcohol Depend       Date:  2017-08-01       Impact factor: 4.492

4.  Implementing statistical methods for generalizing randomized trial findings to a target population.

Authors:  Benjamin Ackerman; Ian Schmid; Kara E Rudolph; Marissa J Seamans; Ryoko Susukida; Ramin Mojtabai; Elizabeth A Stuart
Journal:  Addict Behav       Date:  2018-10-25       Impact factor: 3.913

5.  Association of Medicaid Expansion and Health Insurance with Receipt of Smoking Cessation Services and Smoking Behaviors in Substance Use Disorder Treatment.

Authors:  Deborah Yip; Noah Gubner; Thao Le; Denise Williams; Kevin Delucchi; Joseph Guydish
Journal:  J Behav Health Serv Res       Date:  2020-04       Impact factor: 1.505

6.  Correlating eligibility criteria generalizability and adverse events using Big Data for patients and clinical trials.

Authors:  Anando Sen; Patrick B Ryan; Andrew Goldstein; Shreya Chakrabarti; Shuang Wang; Eileen Koski; Chunhua Weng
Journal:  Ann N Y Acad Sci       Date:  2016-09-06       Impact factor: 5.691

7.  Tobacco and cannabis co-use and interrelatedness among adults.

Authors:  Saima A Akbar; Rachel L Tomko; Claudia A Salazar; Lindsay M Squeglia; Erin A McClure
Journal:  Addict Behav       Date:  2018-11-27       Impact factor: 3.913

8.  Use of multiple tobacco products in a national sample of persons enrolled in addiction treatment.

Authors:  Joseph Guydish; Barbara Tajima; Sowmya Pramod; Thao Le; Noah R Gubner; Barbara Campbell; Paul Roman
Journal:  Drug Alcohol Depend       Date:  2016-07-14       Impact factor: 4.492

9.  Cigarette smoking and quit attempts among Latinos in substance use disorder treatment.

Authors:  Anna Pagano; Noah Gubner; Thao Le; Joseph Guydish
Journal:  Am J Drug Alcohol Abuse       Date:  2018-01-15       Impact factor: 3.829

10.  Diagnostic Assessment of Assumptions for External Validity: An Example Using Data in Metastatic Colorectal Cancer.

Authors:  Michael A Webster-Clark; Hanna K Sanoff; Til Stürmer; Sharon Peacock Hinton; Jennifer L Lund
Journal:  Epidemiology       Date:  2019-01       Impact factor: 4.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.